Literature DB >> 15251170

Midkine promoter-driven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalised and tumour cells.

L Yu1, K Hamada, M Namba, K Kadomatsu, T Muramatsu, S Matsubara, M Tagawa.   

Abstract

We examined possible application of a regulatory region of midkine (MK) gene, which is frequently upregulated in a number of human tumours but not in normal cells, to cancer gene therapy. We examined transcriptional activity of the MK genomic fragments in paired cell lines, immortalized cells and their parental normal fibroblasts, and found that the MK fragments activated a fused reporter or a suicide gene preferentially in the immortalized cells. Recombinant adenoviruses (Ad), in which the MK fragment was inserted upstream to the E1A gene (AdMK), replicated preferentially in the immortalized cells and were cytotoxie to them. Human hepatocellular carcinoma cells were significantly susceptible to AdMK compared with human normal fibroblasts in vitro and the replication of AdMK was less than that of wild-type Ad in the infected fibroblasts. Hepatocellular carcinoma cells infected with AdMK did not form tumours in immunocompromised mice and intratumoural injection of AdMK into the hepatocellular carcinoma developed in mice retarded the subsequent tumour growth. Expression of E1A and necrosis of tumours were detected in AdMK-injected but not control Ad-injected cases. The MK promoter-driven suicide gene therapy and -mediated replicative Ad can thereby produce cytotoxic effects to immortalized and tumour cells with minimal damage to normal cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15251170     DOI: 10.1016/j.ejca.2004.04.014

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  13 in total

1.  Gene therapy that inhibits NF-kappaB results in apoptosis of human hepatocarcinoma by recombinant adenovirus.

Authors:  Tie-Jun Li; Li-Ping Jia; Xiao-Ling Gao; Ai-Long Huang
Journal:  World J Gastroenterol       Date:  2006-09-07       Impact factor: 5.742

2.  Expression of p53 synergistically augments caspases-mediated apoptosis induced by replication-competent adenoviruses in pancreatic carcinoma cells.

Authors:  Y Takei; S Okamoto; K Kawamura; Y Jiang; T Morinaga; M Shingyoji; I Sekine; S Kubo; Y Tada; K Tatsumi; H Shimada; K Hiroshima; N Yamaguchi; M Tagawa
Journal:  Cancer Gene Ther       Date:  2015-08-07       Impact factor: 5.987

3.  Use of the Rad51 promoter for targeted anti-cancer therapy.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-23       Impact factor: 11.205

Review 4.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

Review 5.  Midkine: a promising molecule for drug development to treat diseases of the central nervous system.

Authors:  Takashi Muramatsu
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

6.  Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression.

Authors:  Shan Yang; Kiyoko Kawamura; Shinya Okamoto; Suguru Yamauchi; Masato Shingyoji; Ikuo Sekine; Hiroshi Kobayashi; Yuji Tada; Koichiro Tatsumi; Kenzo Hiroshima; Hideaki Shimada; Masatoshi Tagawa
Journal:  BMC Cancer       Date:  2015-06-10       Impact factor: 4.430

7.  Mesenchymal stem cells are efficiently transduced with adenoviruses bearing type 35-derived fibers and the transduced cells with the IL-28A gene produces cytotoxicity to lung carcinoma cells co-cultured.

Authors:  Takeo Suzuki; Kiyoko Kawamura; Quanhai Li; Shinya Okamoto; Yuji Tada; Koichiro Tatsumi; Hideaki Shimada; Kenzo Hiroshima; Naoto Yamaguchi; Masatoshi Tagawa
Journal:  BMC Cancer       Date:  2014-09-25       Impact factor: 4.430

8.  Midkine promoter-based conditionally replicative adenovirus therapy for midkine-expressing human pancreatic cancer.

Authors:  Eiji Toyoda; Ryuichiro Doi; Kazuhiro Kami; Tomohiko Mori; Daisuke Ito; Masayuki Koizumi; Atsushi Kida; Kazuyuki Nagai; Tatsuo Ito; Toshihiko Masui; Michihiko Wada; Masatoshi Tagawa; Shinji Uemoto
Journal:  J Exp Clin Cancer Res       Date:  2008-08-21

9.  Midkine: a novel prognostic biomarker for cancer.

Authors:  Hirofumi Jono; Yukio Ando
Journal:  Cancers (Basel)       Date:  2010-04-20       Impact factor: 6.639

10.  Utilization of Rad51C promoter for transcriptional targeting of cancer cells.

Authors:  Yan Cao; Yan Xu; Lei Zhang; Zhen Li; Ying Jiang; Xiao Tian; Andrei Seluanov; Vera Gorbunova; Zhiyong Mao
Journal:  Oncotarget       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.